At Molecular Partners we are driven to develop treatments for patients suffering from serious diseases. With a focus on oncology and virology, we are advancing truly differentiated potential treatments for patients through DARPins, the new class of drugs we are pioneering. Our core values as a company are to support our people, the patients we serve. We act as global citizens, committed to creating a more sustainable and healthier world.

To help accomplish all of this, we have identified areas we are prioritizing within our ESG strategy where we feel we can make the greatest positive impact: